Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT07588438

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
Las Rías Medical Center (from the registry)
Registry
  • NCT NCT07588438
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Paraguay (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07588438. Non-randomized; no masking; primary purpose treatment. Start 2026-07-27 (anticipated); primary completion 2027-08-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
Acronym
REAL-TIRZEPY
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.)
Lead sponsor
Las Rías Medical Center (class: other)
Collaborator
LABORATORIO DE PRODUCTOS ETICOS C.E.I.S.A (class: not stated)

Record details

Record id
cardio:ct-nct07588438
Content hash
1635e7af3f02f7bd75853500dd39b0a8f090c82560ac722dcf40d98f6768d8e9